Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 355 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Photography Clear all
Completed Not applicable Interventional

Visible Light Study

NCT02663921
View directory record Official record
Conditions
Skin Disease, Pigment Disorders
Interventions
Part A: Baseline-Week 2, Part B: Week 4-Week 12
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

NCT02348749
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
18F-MFBG (meta-fluoro benzylguanidine), Positron emission tomography (PET) imaging, Blood draws
Radiation · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
5 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 22, 2026, 5:14 AM EDT
Active, not recruiting Not applicable Interventional Results available

RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer

NCT05470699
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computed Tomography, Fluorine F 18 Piflufolastat, Positron Emission Tomography
Procedure · Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Active, not recruiting Early Phase 1 Interventional

Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer

NCT05141643
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
PET Scan
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skin Cancer Screening and Education at Beaches

NCT00894855
View directory record Official record
Conditions
Skin Cancer
Interventions
education about sun protection, biometric feedback, dermatologist skin exam
Behavioral · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 22, 2026, 5:14 AM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging

NCT04348682
View directory record Official record
Conditions
Prostate Cancer
Interventions
Positron Emission Tomography (PET) Imaging
Diagnostic Test
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 22, 2026, 5:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

NCT02769962
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
Interventions
EP0057, olaparib, CT scan, CT chest, abdomen, and pelvis, Bone scan, ECG, Echocardiogram, Biopsy
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Completed No phase listed Observational

Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma

NCT01926990
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
perfusion computed tomography
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 22, 2026, 5:14 AM EDT
Not yet recruiting Phase 1 Interventional

Study Evaluating 68GA-FAPI-46 PET/CT in Patients With Interstitial Lung Disease

NCT07817563
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
⁶⁸Ga-FAPI-46, PET/CT
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

NCT06863233
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions
Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Evaluation of Mallampati Score Changes in Pregnancy

NCT02654067
View directory record Official record
Conditions
Pregnancy
Interventions
photograph
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 22, 2026, 5:14 AM EDT
Terminated No phase listed Observational

F-18 PSMA for Localization of Parathyroid Adenoma

NCT05299632
View directory record Official record
Conditions
Hyperparathyroidism
Interventions
99mTc-MIBI planar imaging and SPECT/CT., F- 18PSMA PET/CT imaging study
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 22, 2026, 5:14 AM EDT
Active, not recruiting Not applicable Interventional

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

NCT03151564
View directory record Official record
Conditions
Diseases of Liver, Colon Carcinoma, Colorectal Carcinoma, Liver Metastases
Interventions
Computed Tomography Scan - 50% Dose Reduction, Computed Tomography Scan - 70% Dose Reduction, Deep Learning Image Reconstruction (DLIR)
Diagnostic Test
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Terminated Phase 1 Interventional

FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

NCT02317302
View directory record Official record
Conditions
Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasms
Interventions
FDG-PET/MR, FDG-PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 22, 2026, 5:14 AM EDT
Recruiting Phase 1 Interventional

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

NCT06062745
View directory record Official record
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Not applicable Interventional Results available

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

NCT02410577
View directory record Official record
Conditions
Glioblastoma
Interventions
89Zr-J591, PET/CT Scan, MRI, Blood draw
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
26 Years to 79 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 22, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer

NCT04511026
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG), Neoprobe Gamma Detection System NPB11L(Model1102)
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 22, 2026, 5:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Effectiveness of Spices and Herbs to Increase Vegetable Intake Among Military

NCT05499858
View directory record Official record
Conditions
Dietary Intake
Interventions
Spiced, Plain
Other
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 5:14 AM EDT
Not yet recruiting Phase 1 Interventional

Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT07682649
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography, Technetium Tc-99m Sulfur Colloid
Procedure · Other · Drug + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Recruiting Phase 2 Interventional

Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma

NCT07050186
View directory record Official record
Conditions
Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomography, Digital Photography, Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 22, 2026, 5:14 AM EDT
Not listed Not applicable Interventional

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

NCT03519659
View directory record Official record
Conditions
PET/CT Imaging
Interventions
PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose
Diagnostic Test
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 22, 2026, 5:14 AM EDT
Active, not recruiting Early Phase 1 Interventional

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

NCT05477823
View directory record Official record
Conditions
Prostate Cancer
Interventions
External beam radiation therapy, Prostate brachytherapy boost, Androgen deprivation therapy, Positron emission tomography (PET)/magnetic resonance imaging (MRI)
Radiation · Drug · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 5:14 AM EDT